Dyne Therapeutics Future Growth
Future criteria checks 0/6
Dyne Therapeutics is forecast to grow earnings and revenue by 19.8% and 62.9% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be -111.5% in 3 years.
Key information
19.8%
Earnings growth rate
20.8%
EPS growth rate
| Biotechs earnings growth | 28.2% |
| Revenue growth rate | 62.9% |
| Future return on equity | -111.5% |
| Analyst coverage | Good |
| Last updated | 22 Jan 2025 |
Recent future growth updates
Recent updates
Dyne Therapeutics: Moving Forward On 2 Key Fronts
Jan 24We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Nov 12
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Nov 11Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street
Sep 04Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth
Aug 14Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials
May 21We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 04Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Jan 12We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth
Sep 29Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down
Jun 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 96 | -376 | -319 | -391 | 6 |
| 12/31/2026 | 5 | -454 | -410 | -397 | 8 |
| 12/31/2025 | N/A | -411 | -387 | -368 | 11 |
| 12/31/2024 | N/A | -326 | -322 | -286 | 11 |
| 9/30/2024 | N/A | -295 | -244 | -243 | N/A |
| 6/30/2024 | N/A | -258 | -220 | -219 | N/A |
| 3/31/2024 | N/A | -257 | -220 | -220 | N/A |
| 12/31/2023 | N/A | -236 | -189 | -188 | N/A |
| 9/30/2023 | N/A | -208 | -184 | -182 | N/A |
| 6/30/2023 | N/A | -189 | -176 | -175 | N/A |
| 3/31/2023 | N/A | -177 | -152 | -150 | N/A |
| 12/31/2022 | N/A | -168 | -157 | -154 | N/A |
| 9/30/2022 | N/A | -181 | -157 | -153 | N/A |
| 6/30/2022 | N/A | -182 | -141 | -137 | N/A |
| 3/31/2022 | N/A | -160 | -157 | -152 | N/A |
| 12/31/2021 | N/A | -149 | -123 | -120 | N/A |
| 9/30/2021 | N/A | -126 | -114 | -112 | N/A |
| 6/30/2021 | N/A | -97 | -98 | -96 | N/A |
| 3/31/2021 | N/A | -77 | -59 | -58 | N/A |
| 12/31/2020 | N/A | -59 | -48 | -47 | N/A |
| 9/30/2020 | N/A | -36 | -32 | -30 | N/A |
| 6/30/2020 | N/A | -28 | -23 | -22 | N/A |
| 3/31/2020 | N/A | -21 | -18 | -17 | N/A |
| 12/31/2019 | N/A | -15 | -13 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DYN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DYN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DYN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DYN is forecast to have no revenue next year.
High Growth Revenue: DYN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DYN is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 23:23 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dyne Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Keay Nakae | Chardan Capital Markets, LLC |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |